Evaluate Pharma. World Preview 2015. 2015. http://info.evaluategroup.com/rs/607-YGS-364/images/wp15.pdf. Accessed 15 Feb 2016.
European Commission—Joint Research Centre. The 2015 EU Industrial R&D investment scoreboard. http://iri.jrc.ec.europa.eu/scoreboard15.html. Accessed 15 Feb 2016.
Munos B. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov. 2009;8:959–68.
Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3:711–6.
Mullard A. 2010 FDA drug approvals. Nat Rev Drug Discov. 2011;10:82–5.
Mullard A. 2011 FDA drug approvals. Nat Rev Drug Discov. 2012;11:91–4.
Mullard A. 2012 FDA drug approvals. Nat Rev Drug Discov. 2013;12:87–90.
Mullard A. 2013 FDA drug approvals. Nat Rev Drug Discov. 2014;13:85–9.
Mullard A. 2014 FDA drug approvals. Nat Rev Drug Discov. 2015;14:77–81.
Schuhmacher A, et al. Value creation in the pharmaceutical industry: the critical path to innovation. Wiley; 2016. ISBN 978-3-527-33913-6.
2014 CMR International Pharmaceutical R&D Factbook.
Paul SM, et al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov. 2010;9:203–14.
DiMasi JA. Risks in new drug development: approval success rates for investigational drugs. Clin Pharmacol Ther. 2001;69:297–307.
Prinz F, et al. Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug Discov. 2011;10:712–3.
Bergren R, et al. Outlook for the next 5 years in drug innovation. Nat Rev Drug Discov. 2012;11:435–6.
Agarwal P. Novelty in the target landscape of the pharmaceutical industry. Nat Rev Drug Discov. 2013;12:575–6.
Sams-Dodd F. Target-based drug discovery: is something wrong? Drug Discov Today. 2005;10:139–47.
Swinney DC, Anthony J. How were new medicines discovered? Nat Rev Drug Discov. 2011;11:507–19.
Scannell JW, et al. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov. 2012;11:191–200.
Pammolli F, et al. The productivity crisis in pharmaceutical R&D. Nat Rev Drug Discov. 2011;10:428–38.
Arrowsmith J, Miller P. Trial Watch: phase II and Phase III attrition rates 2011–2012. Nat Rev Drug Discov. 2013;12:569.
Cook D, et al. Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional framework. Nat Rev Drug Discov. 2014;13:419–31.
DiMasi JA, et al. Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther. 2010;87:272–7.
Abrantes-Metz R et al. Pharmaceutical Development Phases: a duration analysis. Working paper no. 274. US Federal Trade Commission: Bureau of Economics. 2004. http://www.ftc.gov/be/workpapers/wp274.pdf. Accessed 15 Feb 2016.
Hay M, et al. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32:40–51.
Kaitin KI, DiMasi JA. Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000–2009. Clin Pharmacol Ther. 2011;89(2):183–8.
Dickson M, Gagnon JP. Key factors in the rising cost of new drug discovery and development. Nat Rev Drug Discov. 2004;3:417–29.
DiMasi JA. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;23:151–85.
DiMasi JA. Cost of innovation in the pharmaceutical industry. J Health Econ. 1991;10:107–42.
Harper M. The truly staggering cost of inventing new drugs. 2012. http://www.forbes.com/sites/matthewherper/2012/02/10/the-truly-staggering-cost-of-inventing-newdrugs/#2ce906714477.
Danzon PM. Mergers and acquisitions in the pharmaceutical and biotech industries. Manag Decis Econ. 2007;28:307–28.
LaMattina JL. The impact of mergers on pharmaceutical R&D. Nat Rev Drug Discov. 2011;10:559–60.
Ornaghi C. Mergers and innovation in big pharma. Int J Ind Organ. 2009;27:70–9.
Comanor WS, Scherer FM. Mergers and innovation in the pharmaceutical industry. J Health Econ. 2013;32:106–13.
DiMasi JA, et al. The impact of collaborative and risk-sharing innovation approaches on clinical and regulatory cycle times. Ther Innov Regul Sci. 2014;48:482–7.
Kruse S, et al. Pharmaceutical RandD productivity: the role of alliances. J Commer Biotechnol. 2014;20:11–20.
Garnier JP. Rebuilding the R&D engine in big pharma. Harv Bus Rev. 2008;86:68–79.
Douglas FL, et al. The case for entrepreneurship in R&D in the pharmaceutical industry. Nat Rev Drug Discov. 2010;9:683–9.
Tralau-Stewart CJ, et al. Drug discovery: new models for industry-academic partnerships. Drug Discov Today. 2009;14:95–101.
Regalado A. Money seeks idea. MIT. Technol Rev. 2012;115(6):75–6.
Ekins S, et al. Four disruptive strategies for removing drug discovery bottlenecks. Drug Discov Today. 2013;18:265–71.
Frye S, et al. US academic drug discovery. Nat Rev Drug Discov. 2011;10:409–10.
Kling J. Biotechs follow big pharma lead back into academia. Nat Biotechnol. 2011;29:555–6.
Schuhmacher A, et al. Models for open innovation in the pharmaceutical industry. Drug Discov Today. 2013;18:1133–7.
Citeline. Pharma R&D annual review. 2013. http://www.citeline.com/wp-content/uploads/Annual-Review-2014b.pdf. Accessed 28 Oct 2014.
KPMG. Outsourcing in the pharmaceutical industry: 2011 and beyond. 2012 https://www.kpmg.com/Ca/en/IssuesAndInsights/ArticlesPublications/Documents/Outsourcing-pharmaceutical-industry.pdf. Accessed 15 Mar 2016.
Mehta S, Peters LS. Outsourcing a core competency. Res Technol Manag. 2007;5:28–33.
Clark DE. Outsourcing lead optimization: the eye of the storm. Drug Discov Today. 2010;16:147–57.
Kermani F. Drug discovery partnerships between UK CROs and the Swiss pharma sector. Pharm Technol Eur. 2014;26:8–11.
Levy H. Integrated outsourcing transforms and increases R&D productivity. J Commer Biotechnol. 2013;19:49–54.
Ratner M. Pfizer reaches out to academia—again. Nat Biotechnol. 2011;29:3–4.
Harrison C. GlaxoSmithKline opens the door on clinical data sharing. Nat Rev Drug Discov. 2011;11:891–2.
Strauss S. Pharma embraces open source models. Nat Biotechnol. 2010;7:631–4.
Munos B. Can open-source drug R&D repower pharmaceutical innovation? Clin Pharmacol Ther. 2010;87:534–6.
Roijakkers N, Hagedorn J. Inter-firm R&D partnering in pharmaceutical biotechnology since 1975: trends, patterns, and networks. Res Policy. 2006;35:431–46.
Lessl M, et al. Grants4Targets– an innovative approach to translate ideas from basic research into novel drugs. Drug Discov Today. 2011;16:288–92.
Dorsch H, et al. Grants4Targets—an open innovation initiative to foster drug discovery collaborations between academia and the pharmaceutical industry. Nat Rev Drug Discov. 2015;14:74–6.
Owens PK. A decade of innovation in pharmaceutical R&D: the Chorus model. Nat Rev Drug Discov. 2015;14:17–28.
Longman R. Lilly‘s chorus experiment. In Vivo. 2007;25(5):1–5.
PWC. Pharma emerging markets 2.0. 2013. http://www.strategyand.pwc.com/media/file/Strategyand_Pharma-Emerging-Markets-2.0.pdf. Accessed 15 Nov 2015.
KPMG. Future Pharma. 2011. https://www.kpmg.com/BE/en/IssuesAndInsights/ArticlesPublications/Documents/future-pharma.pdf. Accessed 15 Nov 2015.